We demonstrate that the androgen receptor (AR) regulates a transcriptional program of DNA repair genes that promotes prostate cancer radioresistance, providing a potential mechanism by which androgen deprivation therapy (ADT) synergizes with ionizing radiation (IR). Using a model of castration-resistant prostate cancer, we show that second-generation antiandrogen therapy results in downregulation of DNA repair genes. Next, we demonstrate that primary prostate cancers display a significant spectrum of AR transcriptional output which correlates with expression of a set of DNA repair genes. Employing RNA-seq and ChIP-seq, we define which of these DNA repair Author Manuscript Published OnlineFirst on DOI: 10.1158/2159 3
Introduction
Multiple clinical trials comparing radiotherapy (RT) plus androgen deprivation therapy (ADT) versus RT alone for high-risk prostate cancer, and more recently intermediate-risk, show significant improvement in disease-free and overall survival with the addition of ADT (1, 2) . Furthermore, post-treatment biopsy series demonstrate improved local control when ADT is added to RT (3) . In light of these and other studies, combining ADT with RT for high-risk prostate cancer has been the standard of care for nearly twenty years, yet the mechanism by which ADT improves patient outcomes remains unknown. Furthermore, it is unknown whether ADT benefits a subset of patients substantially or all patients with prostate cancer to a smaller degree.
Given the compelling body of clinical evidence, many have sought to elucidate how inhibiting the androgen receptor (AR) potentiates ionizing radiation (IR). Using in vitro and in vivo models, the addition of ADT to IR has been shown to increase prostate cancer cell death (4) . A number of mechanisms have been explored to explain the increase in cell death when ADT is combined with IR, including decreased tumor cell hypoxia (5), decreased DNA repair (6) , or simply decreased AR-mediated cell growth independent of direct synergy (7) . Surprising light has recently been shed on additional inter-relationships between AR and DNA repair, including a role for AR in mediating prostate-cancer specific translocations following high-dose IR (8) and the discovery that the DNA repair protein, PARP1, is an important co-factor for AR transcriptional activity (9) .
Defining the mechanism by which ADT increases prostate cancer radioresponse has never been more clinically relevant given the recently demonstrated success of second-generation anti-androgens in the treatment of castration-resistant patients (10, 11) . Given the clinical potential of deploying these new agents as part of radiotherapy for primary disease coupled with the ability now to leverage prostate cancer genomics data to help define genetic mechanisms in a less biased way, it is critical to re-examine the basic biologic question of how AR signaling promotes prostate cancer radioresistance.
Results
We began with an unbiased query of how gene expression is perturbed when a clinically validated xenograft model of castration-resistant prostate cancer, LNCaP-AR, is treated with the second-generation anti-androgen, ARN-509 (12, 13) . After four days of treatment with ARN-509, transcriptome analysis was performed by Illumina HT12 expression array. Standard gene set enrichment analysis (GSEA) was performed, and, to our surprise, three out of the top ten gene sets that were enriched in the control versus ARN-509-treated groups represented DNA repair gene sets; in total, 6 DNA repair gene sets comprised the top 50 enriched gene sets (Fig. 1A , Supplementary   Table S1 ).
Given the unexpected result of ADT decreasing DNA repair gene expression in the castration-resistant model, we next sought to determine whether there was an association of AR transcriptional output with DNA repair genes in primary, castrationsensitive human prostate tumors (14) . This set of primary prostate cancer tumors
represents the appropriate group to analyze since this is the disease state treated with ADT and RT. First, we determined the variance of canonical AR transcriptional output, using a well-known signature derived by Hieronymus et al. (14, 15) human prostate cancer tumors. Again, to our surprise, we observed a large spectrum of canonical AR output (Fig. 1B) . Given this variance of AR output across primary prostate cancer tumors, we next asked whether there was a correlation between a composite score of canonical AR output, as previously calculated (16) , and a composite score of the enriched DNA repair genes from the previous xenograft experiment. Upon this analysis, we indeed found a significant correlation (p<0.001) between canonical AR output and the enriched DNA repair genes (Fig. 1C) . Next, in order to define the most robust signature of AR-associated DNA repair genes without limiting ourselves to the enriched genes from the initial xenograft experiment, we more broadly asked which of the DNA repair genes in all of the six combined DNA repair gene sets (294 genes) were most associated with canonical AR output in the primary human prostate cancer data set (Fig. 1D, Supplementary Table S2 ). Filtering for an association with canonical AR output (p<0.01 and r>0), we defined an "AR-associated DNA repair gene" signature of 144 DNA repair genes that were significantly associated with canonical AR output.
Given the association of canonical AR output with DNA repair gene expression in primary prostate cancers, we next sought to determine using an in vitro model which, if any, of these DNA repair genes are transcriptionally regulated by androgen. We Fig. 2A) (17) . Of the 144 genes that comprise the AR-associated DNA repair signature, we next identified those genes whose expression was increased by androgen and which contained AR binding sites (Fig. 2B) . 32 genes were both induced by androgen and exhibited AR peaks in their enhancers (32) or promoter (1) , suggesting that these represented bona fide AR target genes ( Fig. 2B and 2C, Supplementary Fig. 2 ). Motif analysis of the AR binding peaks of these 32 genes revealed the classic consensus AR-binding site (Fig.   2D ).
We next sought to determine whether the reduction in DNA repair gene expression observed with androgen deprivation was associated with (1) reduced DNA repair and (2) increased DNA damage. Using the same in vitro LNCaP model, we exposed prostate cancer cells, pretreated for two days with either synthetic androgen (1 nM R1881) or mock (DMSO), to 2 Gy of IR and gamma-H2AX foci were quantified.
Comparing the gamma-H2AX foci in the two conditions, we found that in androgendepleted conditions the foci peaked later and higher and resolved more slowly, consistent with decreased repair (Fig. 3A) . Since gamma-H2AX foci represent a surrogate, indirect marker of unrepaired breaks, we next sought to measure DNA damage itself. To do so, we employed the neutral Comet assay that directly measures double-strand DNA breaks. The findings of the Comet assay under the same conditions recapitulated the results obtained analyzing gamma-H2AX foci ( cells, we next sought to determine which of DNA repair pathways are functionally abrogated by ARN-509 (Fig. 4A) . Since the DNA double-strand breaks (DSBs) induced by IR are thought to be repaired by classical nonhomologous end-joining (C-NHEJ) and homologous recombination (HR), we focused upon these repair pathways.
In order to assess the effects of antiandrogen treatment on C-NHEJ, we employed the transient V(D)J recombination assay as previously described ( (Fig. 4C, Supplementary Fig. S4 ). Next, to assess the effects of antiandrogen treatment on HR, we utilized the transient DR-GFP assay, a widely used repair reporter assay for studying HR (Fig. 4D) (20) . DR-GFP contains direct repeats of two defective GFP genes with the upstream repeat containing a recognition site for the I-SceI 
observed between the treated and control cells, in contrast to the 2.8 fold reduction in HR observed with expression of BRC3, a peptide known to interfere with HR ( Fig. 4E) (21).
Discussion
Androgens, acting through AR, regulate a complex transcriptional program for both prostate cancer growth and differentiation, with recent data demonstrating unique sets of AR target genes in castration-sensitive versus castration-resistant tumors (22) .
In this study, we discover a network of DNA repair genes that comprises part of the complex AR-regulated transcriptome. Our data establish that AR signaling increases the expression of DNA repair genes and, in parallel, promotes prostate cancer radioresistance by accelerating repair of IR-induced DNA damage. Collectively, these data provide strong mechanistic rationale for the observed synergy between ADT and RT.
Clinical trials of ADT plus RT have been unable to answer the question of whether ADT benefits all patients modestly or a subset to a greater degree. The surprising spectrum of AR output that we observe in primary prostate cancer tumors suggests that ADT may preferentially benefit those patients with high AR transcriptional output and, consequently, high expression of DNA repair genes. Therefore, in a similar manner that breast cancer patients are selected for anti-estrogen therapy by a molecular determinant of response (ER/PR status), perhaps it is possible to select prostate cancer patients who will receive ADT along with RT (as opposed to RT alone) based upon a tumor's AR output. This hypothesis could be tested using pathologic specimens from one of the landmark clinical trials comparing ADT and RT to RT alone. 
The discovery that AR activity, among its other known biologic effects, also regulates DNA repair could have implications beyond the question of how ADT synergizes with RT. First, the finding that C-NHEJ can be dynamically modulated via inhibition of a nuclear hormone receptor/transcription factor represents a new kind of mechanism by which to abrogate this important pathway. Second, it remains to be determined whether the other identified AR-regulated DNA repair genes play a functional role in their respective pathways (e.g. mismatch repair, base excision repair, Fanconi pathway) when their expression levels are modulated by AR (Fig. 4A) . Finally, recent genomic studies demonstrate that in comparison to primary tumors, one of the hallmarks of CRPC appears to be widespread genomic instability (14, 23) LNCaP RNA-Seq/ChiP-Seq: LNCaP cells were grown in described conditions in triplicate and RNA was isolated by Rneasy Mini Kit (Qiagen) with the additional steps of lysate homogenization using QIAshredder (Qiagen) and DNase digestion using RNaseFree DNase Set (Qiagen). Samples were prepared and libraries created using TruSeq RNA Sample Preparation Kit v2 (Illumina), which included a poly A selection step.
Libraries were pooled at 2 nm concentration and the samples were then subject to cBot cluster generation using TruSeq Rapid PE Cluster Kit (Illumina). The amplified libraries were sequenced using the TruSeq Rapid SBS Kit on the HiSeq 2500 (Illumina).
mRNA-seq data were aligned with Mapsplice (25) Lethally irradiated HeLa feeder cells (400,000) were added to each well to promote colony formation. Plates were incubated for 14 days, then washed and fixed with methanol, and stained with 0.2% crystal violet (Sigma) in 10% formalin (Sigma). Plates were scanned by GelCount (Oxford Optronix), and colonies were counted using GelCount software. Clonogenic survival curves were generated as previously described.
Western blot analysis: Whole cell lysates were prepared using 10% M-PER lysis buffer 
